MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat

MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat

Abstract Background Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line platinum-based doublet chemotherapy, but almost universally relapse wi...

Full description

Bibliographic Details
Main Authors: Jasmine Chen, Aleks C. Guanizo, W. Samantha N. Jakasekara, Chaitanya Inampudi, Quinton Luong, Daniel J. Garama, Muhammad Alamgeer, Nishant Thakur, Michael DeVeer, Vinod Ganju, D. Neil Watkins, Jason E. Cain, Daniel J. Gough
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Small cell lung cancer
Platinum resistance
Mouse models
MYC
Fimepinostat
Online Access:https://doi.org/10.1186/s13046-023-02678-1

Internet

https://doi.org/10.1186/s13046-023-02678-1

Similar Items